stock-detail (KITE)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/19/2017 06:18 am

4/19/2017 06:18 am

4/19/2017 06:18 am

4/19/2017 06:18 am

4/18/2017 12:18 am

4/18/2017 12:18 am

4/18/2017 12:18 am

4/11/2017 06:17 pm

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

4/2/2017 08:00 pm

[Business Wire] - Kite Pharma, Inc., today announced two plenary presentations of positive data from the primary analysis of ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel, in patients with refractory aggressive B-cell non-Hodgkin lymphoma at the 2017 American Association of Cancer Research Annual Meeting in Washington, D.C.

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

3/31/2017 07:01 pm

[Business Wire] - Kite Pharma, Inc. today announced that it has completed the rolling submission with the U.S. Food and Drug Administration of the Biologics License Application for axicabtagene ciloleucel as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant .